Short and long-term tumor cell responses to Aurora kinase inhibitors - PubMed (original) (raw)
. 2009 Apr 15;315(7):1085-99.
doi: 10.1016/j.yexcr.2009.02.008. Epub 2009 Feb 20.
Affiliations
- PMID: 19233169
- DOI: 10.1016/j.yexcr.2009.02.008
Short and long-term tumor cell responses to Aurora kinase inhibitors
Megan R Dreier et al. Exp Cell Res. 2009.
Abstract
Aurora kinases are essential for mitosis and are candidate targets of novel chemotherapeutic agents. The inhibitors ZM447439, MK-0457 (VX-680) as well as Hesperadin have been used to dissect the roles of Aurora kinases in the cell cycle and have been tested clinically for the treatment of cancer. Here we have carried out a detailed kinetic analysis of two isogenic cell lines differing in p53 function and have compared the effects of ZM447439 and VE-465 (related to MK-0457). We find that p53 is needed for efficient cell cycle arrest when Aurora kinases are inhibited by either ZM447439 or VE-465. However, the p53-induced cell cycle block is neither immediate nor absolute. ZM447439 induced the localized accumulation of gammaH2A.X indicating that p53 induction by this drug occurs in response to DNA damage. Our analysis of the long-term effects of ZM447439 indicates that cells can evade killing by the drug, but not via a classical drug-resistance mechanism. Several mechanisms to explain how cells may evade killing by Aurora kinase inhibitors are described.
Similar articles
- Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Walsby E, et al. Haematologica. 2008 May;93(5):662-9. doi: 10.3324/haematol.12148. Epub 2008 Mar 26. Haematologica. 2008. PMID: 18367484 - Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.
Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H, Micksche M, Grusch M, Berger W. Pirker C, et al. Exp Dermatol. 2010 Dec;19(12):1040-7. doi: 10.1111/j.1600-0625.2010.01182.x. Exp Dermatol. 2010. PMID: 21087322 - Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Kaestner P, Stolz A, Bastians H. Kaestner P, et al. Mol Cancer Ther. 2009 Jul;8(7):2046-56. doi: 10.1158/1535-7163.MCT-09-0323. Epub 2009 Jul 7. Mol Cancer Ther. 2009. PMID: 19584233 - Dawn of Aurora kinase inhibitors as anticancer drugs.
Doggrell SA. Doggrell SA. Expert Opin Investig Drugs. 2004 Sep;13(9):1199-201. doi: 10.1517/13543784.13.9.1199. Expert Opin Investig Drugs. 2004. PMID: 15330750 Review. - The role of Aurora-A inhibitors in cancer therapy.
Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. Agnese V, et al. Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52. doi: 10.1093/annonc/mdm224. Ann Oncol. 2007. PMID: 17591831 Review.
Cited by
- Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N. Patel AV, et al. Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18. Clin Cancer Res. 2012. PMID: 22811580 Free PMC article. - Microtubule-associated proteins promote microtubule generation in the absence of γ-tubulin in human colon cancer cells.
Tsuchiya K, Goshima G. Tsuchiya K, et al. J Cell Biol. 2021 Dec 6;220(12):e202104114. doi: 10.1083/jcb.202104114. Epub 2021 Nov 15. J Cell Biol. 2021. PMID: 34779859 Free PMC article. - Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases.
Jane EP, Premkumar DR, Rajasundaram D, Thambireddy S, Reslink MC, Agnihotri S, Pollack IF. Jane EP, et al. Mol Oncol. 2022 Jan;16(1):219-249. doi: 10.1002/1878-0261.13025. Epub 2021 Jun 23. Mol Oncol. 2022. PMID: 34058053 Free PMC article. - Targeting bromodomain and extraterminal proteins in breast cancer.
Sahni JM, Keri RA. Sahni JM, et al. Pharmacol Res. 2018 Mar;129:156-176. doi: 10.1016/j.phrs.2017.11.015. Epub 2017 Nov 16. Pharmacol Res. 2018. PMID: 29154989 Free PMC article. Review. - Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression.
Joshi S, Braithwaite AW, Robinson PJ, Chircop M. Joshi S, et al. Mol Cancer. 2011 Jun 28;10:78. doi: 10.1186/1476-4598-10-78. Mol Cancer. 2011. PMID: 21708043 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous